{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:06:42Z","timestamp":1793066802382,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"19","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Numerous medications have been approved to treat heart failure (HF). Given the risk of irreversible morbidity and mortality in chronic HF, medication approval was traditionally based upon reductions in cardiovascular death or HF hospitalization. However, expanding use of effective medicines has reduced hospitalization and mortality rates. This incremental reduction in \u2018hard\u2019 outcomes has made endpoints that capture how patients feel or function attractive for new medicine development as efficacy can potentially be demonstrated in smaller trials of shorter duration than cardiovascular outcome trials. Moreover, while inpatient hospitalization is the traditional vehicle for managing acute HF, dedicated infusion centres, observation units, and emergency departments now provide alternative outpatient venues. This changing clinical practice landscape prompts consideration of certain outpatient HF events as reasonable for inclusion in a primary composite endpoint, though these events span a broad spectrum of severity of worsening HF. At the high severity margin, outpatient events approximate a hospitalization equivalent, i.e. but for the existence of alternative venues, patients would have been hospitalized. At the opposite end of the continuum are changes in care without direct contact, e.g. increasing oral diuretics after a brief telephone call. Both events ostensibly represent clinical worsening yet differ markedly in patient relevance. Building upon previous guidance documents, a contemporary regulatory perspective is presented on innovating, standardizing, and streamlining HF trials. Adoption of these principles may improve trial efficiency while ensuring new therapies possess unambiguous public health benefits.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehag069","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:42:30Z","timestamp":1769172150000},"page":"2245-2254","source":"Crossref","is-referenced-by-count":5,"title":["Heart failure endpoints in Food and Drug Administration pivotal trials"],"prefix":"10.1093","volume":"47","author":[{"given":"Mori J","family":"Krantz","sequence":"first","affiliation":[{"name":"Division of Cardiology and Nephrology (DCN), Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN), Office of New Drugs, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA) , 10903 New Hampshire Ave, Building 22, Room 4164, Silver Spring, MD 20993 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Senatore","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Nephrology (DCN), Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN), Office of New Drugs, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA) , 10903 New Hampshire Ave, Building 22, Room 4164, Silver Spring, MD 20993 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell A","family":"Psotka","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Nephrology (DCN), Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN), Office of New Drugs, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA) , 10903 New Hampshire Ave, Building 22, Room 4164, Silver Spring, MD 20993 ,","place":["USA"]},{"name":"Inova Schar Heart and Vascular, Farifax, VA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Fiuzat","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Nephrology (DCN), Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN), Office of New Drugs, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA) , 10903 New Hampshire Ave, Building 22, Room 4164, Silver Spring, MD 20993 ,","place":["USA"]},{"name":"School of Medicine, Duke University, Durham, NC, USA Department of Medicine, Cardiology Division,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ross","family":"Southworth","sequence":"additional","affiliation":[{"name":"Retired DCN, OCHEN, CDER, FDA, Silver Spring, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Stockbridge","sequence":"additional","affiliation":[{"name":"Retired DCN, OCHEN, CDER, FDA, Silver Spring, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2026051815271340600_ehag069-B1","author":"US Food and Drug Administration"},{"key":"2026051815271340600_ehag069-B2","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","article-title":"Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America","volume":"29","author":"Bozkurt","year":"2023","journal-title":"J Card Fail"},{"key":"2026051815271340600_ehag069-B3","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.15420\/cfr.2021.18","article-title":"The gap to fill: rationale for rapid initiation and optimal titration of comprehensive disease-modifying medical therapy for heart failure with reduced ejection fraction","volume":"7","author":"Bronwell","year":"2021","journal-title":"Card Fail Rev"},{"key":"2026051815271340600_ehag069-B4","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/ejhf.2727","article-title":"Outpatient versus inpatient intravenous diuretic therapy for heart failure in the United States","volume":"24","author":"Greene","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026051815271340600_ehag069-B5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/CLEP.S341919","article-title":"Characterizing a clinical trial\u2014representative, real-world population with heart failure with reduced ejection fraction","volume":"14","author":"Wells","year":"2022","journal-title":"Clin Epidemiol"},{"key":"2026051815271340600_ehag069-B6","volume-title":"Treatment for Heart Failure: Endpoints for Drug Development. Guidance for Industry","author":"US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)","year":"2019"},{"key":"2026051815271340600_ehag069-B7","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1161\/CIRCULATIONAHA.124.072158","article-title":"Patient-reported outcomes as end points in heart failure trials","volume":"151","author":"Butler","year":"2025","journal-title":"Circulation"},{"key":"2026051815271340600_ehag069-B8","volume-title":"Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making","author":"US Food and Drug Administration","year":"2023"},{"key":"2026051815271340600_ehag069-B9","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"2026051815271340600_ehag069-B10","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1164\/rccm.202208-1547OC","article-title":"Minimal clinically important difference in the 6-minute-walk distance for patients with pulmonary arterial hypertension","volume":"207","author":"Moutchia","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026051815271340600_ehag069-B11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/pst.2273","article-title":"Should responder analyses be conducted on continuous outcomes?","volume":"22","author":"Abugov","year":"2023","journal-title":"Pharm Stat"},{"key":"2026051815271340600_ehag069-B12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(06)69201-5","article-title":"Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials","volume":"368","author":"Dagenais","year":"2006","journal-title":"Lancet"},{"key":"2026051815271340600_ehag069-B13","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jacc.2021.11.033","article-title":"Optimal background pharmacological therapy for heart failure patients in clinical trials. JACC review topic of the week","volume":"79","author":"Fiuzat","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026051815271340600_ehag069-B14","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jchf.2020.07.005","article-title":"Utility of restricted mean survival time analysis for heart failure clinical trial evaluation and interpretation","volume":"8","author":"Perego","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026051815271340600_ehag069-B15","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026051815271340600_ehag069-B16","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2415471","article-title":"Digitoxin in patients with heart failure and reduced ejection fraction","volume":"393","author":"Bavendiek","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051815271340600_ehag069-B17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cardfail.2007.12.008","article-title":"Inpatient initiation of beta-blockade plus nurse management in vulnerable heart failure patients: a randomized study","volume":"14","author":"Krantz","year":"2008","journal-title":"J Card Fail"},{"key":"2026051815271340600_ehag069-B18","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/j.jacc.2025.03.543","article-title":"Re-evaluating recurrent events in heart failure trials: patterns, prognostic implications, and analytical improvements","volume":"85","author":"Hazewinkel","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026051815271340600_ehag069-B19","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1161\/CIRCULATIONAHA.121.054496","article-title":"Probabilistic readjudication of heart failure hospitalization events in the PARAGON-HF study","volume":"143","author":"Felker","year":"2021","journal-title":"Circulation"},{"key":"2026051815271340600_ehag069-B20","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1093\/eurheartj\/ehae753","article-title":"Centrally adjudicated vs. investigator-reported outcomes in randomized heart failure trials","volume":"45","author":"Wandel","year":"2024","journal-title":"Eur Heart J"},{"key":"2026051815271340600_ehag069-B21","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/ejhf.2874","article-title":"Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology","volume":"25","author":"Metra","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026051815271340600_ehag069-B22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","article-title":"2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards)","volume":"66","author":"Hicks","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026051815271340600_ehag069-B23","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jchf.2020.10.002","article-title":"Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium","volume":"8","author":"Abraham","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026051815271340600_ehag069-B24","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/ejhf.3230","article-title":"Cause-specific death in heart failure across the ejection fraction spectrum: a comprehensive assessment of over 100","volume":"26","author":"Settergren","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026051815271340600_ehag069-B25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jama.2025.10116","article-title":"Priorities for a new FDA","volume":"334","author":"Makary","year":"2025","journal-title":"JAMA"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag069\/66586152\/ehag069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/19\/2245\/66586152\/ehag069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/19\/2245\/66586152\/ehag069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T19:27:20Z","timestamp":1779132440000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/19\/2245\/8441723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":25,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,1,30]]},"published-print":{"date-parts":[[2026,5,18]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag069","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,14]]},"published":{"date-parts":[[2026,1,30]]}}}